Navigation Links
Roche, Baylor Research Institute Partner in Human Immunology Research
Date:12/3/2010

DALLAS, Dec. 3, 2010 /PRNewswire-USNewswire/ -- Baylor Research Institute (BRI), the research arm of Baylor Health Care System, announced that it has formed a three-year partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop programs emerging from the human immunology platforms developed at the Baylor Institute for Immunology Research (BIIR), a component of BRI.

These programs will leverage BIIR's leading position in human immunology with particular focus on cancer vaccines, auto-immune disease diagnostics and treatment, proprietary platforms in biosignature and antibody development, with a view at identifying new leads that could be in-licensed by Roche. A Joint Research Committee will determine the most promising projects in that context, to be funded by Roche over a three-year period.

BRI will retain sole responsibility for programs outside the jointly developed projects.

"The worldwide reputation in human immunology established by Jacques Banchereau  and his team over the years and the uniqueness of some of their programs clearly fit Roche's strategic discovery plans for novel approaches in diagnosing and treating diseases where our company wants to expand its franchise," said Jean-Jacques Garaud, MD., Head of Roche Pharma Research & Early Development (pRED).

Banchereau, formerly the director at BIIR, is senior vice president, head of the Inflammation and Virology Discovery and Translational Areas and chief scientific officer at Roche.

"The partnership with a world leader such as Roche will help tremendously in accelerating the translation of our leading innovative science in human immunology, into diagnostics and treatments that will benefit patients worldwide," said Michael A.E. Ramsay, MD., FRCA, president of BRI.

About BRI: Established in 1984 in Dallas, Texas, Baylor Research Institute (BRI) promotes and supports research to bring innovative treatments from the laboratory workbench to the patient bedside. To achieve this bench-to-bedside concept, BRI focuses on basic science, clinical trials, healthcare effectiveness and quality of care research. Today, BRI is conducting more than 800 active research protocols with 250 research investigators, spanning more than 20 medical specialties, and has research and development projects in areas ranging from human immunology and orphan metabolic diseases to diabetes, cardio-vascular disease and many other unmet medical needs.

www.baylorhealth.edu/Research/FOR MORE INFORMATION, CONTACT: Kristine Hughes Communications Coordinator 214-820-7556 (O) kristine.hughes@baylorhealth.edu
'/>"/>

SOURCE BAYLOR RESEARCH INSTITUTE
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ambry Genetics Announces the Addition of Array CGH Services Through Partnership With Baylor College of Medicine
2. Leading LASIK Laser Eye Cataract Surgery Experts of Baylor Vision in Houston Join Trusted LASIK Surgeons Directory
3. NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes
4. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
5. Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members
6. Melior Enters Research Collaboration with AstraZeneca
7. UC Riverside researcher develops novel method to grow human embryonic stem cells
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
9. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
10. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
11. Cyntellect to Collaborate With the Burnham Institute for Medical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Nova Oculus Partners has forged ... medical device for the treatment of Age-Related Macular Degeneration. , The company’s chief ... regulatory consultancy that helps companies like ours secure government approvals for their medical ...
(Date:1/21/2017)... LEAWOOD, Kan. , Jan. 20, 2017 ... pet therapeutics company focused on the licensing, development and ... Animal Pharm,s Best Company in ... was granted the award based on the ... ® (grapiprant tablets), ENTYCE ® (capromorelin oral ...
(Date:1/20/2017)... , January 20, 2017 ... market conditions have influenced the most recent performances of ... Inc. (NASDAQ: RGLS ), Abeona Therapeutics Inc. ... TBPH ), and Sage Therapeutics Inc. (NASDAQ: ... report by Grand View Research, global Biotech market size is expected ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... announced today the next evolution in spinal fusion, the MISquito Percutaneous Pedicle ... to the competition, SpineFrontier is focused on technique driven product solutions that ...
Breaking Biology Technology:
(Date:12/15/2016)... ... Markets has announced the addition of the "Global Military Biometrics Market ... the global military biometrics market to grow at a CAGR of 7.5% ... based on an in-depth market analysis with inputs from industry experts. The ... years. The report also includes a discussion of the key vendors operating ...
(Date:12/15/2016)... 14, 2016 "Increase in mobile transactions is ... mobile biometrics market is expected to grow from USD ... 2022, at a CAGR of 29.3% between 2016 and ... the growing demand for smart devices, government initiatives, and ... "Software component is expected to grow at a high ...
(Date:12/8/2016)... 2016  Singulex, Inc., the leader in Next Generation ... a license and supply agreement with Thermo Fisher Scientific, ... Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), a ... used to diagnose systemic bacterial infection and sepsis and ... aid in assessing the risk of critically ill patients ...
Breaking Biology News(10 mins):